We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Results from a pivotal trial of a new HIV therapy, show that PRO 140 is an effective, long-acting therapeutic for previously treated HIV-1 infected patients…
Gilead Sciences announced results from a Phase II study demonstrating that the experimental integrase strand transfer inhibitor bictegravir achieved high virologic response rates similar to ViiV Healthcare's integrase inhibitor Tivicay (dolutegravir) in t